Leuprorelin Acetate Long-Lasting Effects on GnRH Receptors of Prostate Cancer Cells: An Atomic Force Microscopy Study of Agonist/Receptor Interaction

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Lama, Gina ^a   Papi, Massimiliano ^a   Angelucci, Cristiana ^a   Maulucci, Giuseppe ^a   Sica, Gigliola ^a   de Spirito, Marco ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN RECEPTOR; LEUPRORELIN;

ARTICLE; ATOMIC FORCE MICROSCOPY; BINDING AFFINITY; BINDING SITE; CANCER CELL; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; EMBRYO; HUMAN; HUMAN CELL; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, HORMONAL; BINDING SITES; BINDING, COMPETITIVE; BLOTTING, WESTERN; CELL LINE, TUMOR; GONADOTROPIN-RELEASING HORMONE; HEK293 CELLS; HUMANS; LEUPROLIDE; MALE; MICROSCOPY, ATOMIC FORCE; PROSTATIC NEOPLASMS; RECEPTORS, LHRH;

EID: 84872245741     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052530     Document Type: Article

References (52)

1. Labrie F, (1995) Endocrine therapy of prostate cancer: optimal form and timing. J Clin Endocrinol Metab 80: 1066-1071.
2. Green S, Furr B, (1999) Prospects for the treatment of endocrine-responsive tumours. Endocr Relat Cancer 6: 349-371.
3. Manni A, (1999) Hormonal approaches to the chemoprevention of endocrine-dependent tumors. Endocr Relat Cancer 6: 483-485.
4. Kakar SS, Jennes L, (1995) Expression of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor mRNAs in various non-reproductive human tissues. Cancer Lett 98: 57-62.
5. Kahán Z, Arencibia JM, Csernus VJ, Groot K, Kineman RD, et al. (1999) Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers. J Clin Endocrinol Metab 84: 582-589.
6. Qayum A, Gullick W, Clayton RC, Sikora K, Waxman J, (1990) The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. Br J Cancer 62: 96-99.
7. Kakar SS, Grizzle WE, Neill JD, (1994) The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary. Mol Cell Endocrinol 106: 145-149.
8. Miller WR, Scott WN, Morris R, Fraser HM, Sharpe RM, (1985) Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 313: 231-233.
9. Limonta P, Dondi D, Moretti RM, Maggi R, Motta M, (1992) Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 75: 207-212.
10. Emons G, Schröder B, Ortmann O, Westphalen S, Schulz KD, et al. (1993) High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab 77: 1458-1464.
11. Dondi D, Limonta P, Moretti RM, Montagnani Marelli M, Garattini E, et al. (1994) Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. Cancer Res 54: 4091-4095.
12. Moretti RM, Montagnani Marelli M, van Groeninghen JC, Motta M, Limonta P, (2003) Inhibitory activity of luteinizing hormone-releasing hormone on tumor growth and progression. Endocr Relat Cancer 10: 161-167.
13. Gründke C, Schlotawa L, Viereck V, Eicke N, Horst A, et al. (2004) Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor. Eur J Endocrinol 151: 141-149.
14. Föst C, Duwe F, Hellriegel M, Schweyer S, Emons G, et al. (2011) Targeted chemotherapy for triple-negative breast cancers via LHRH receptor. Oncol Rep 25: 1481-1487.
15. Sica G, Iacopino F, Marini L, Robustelli della Cuna G, (1992) Antiproliferative effect of leuprorelin acetate, alone or combined with tamoxifen or medroxyprogesterone acetate, on human breast cancer cell lines. Clin Ther 14: 87-96.
16. Marini L, Iacopino F, Schinzari G, Robustelli della Cuna FS, Mantovani G, et al. (1994) Direct antiproliferative effect of triptorelin on human breast cancer cells. Anticancer Res 14: 1881-1885.
17. Sica G, Iacopino F, Robustelli della Cuna G, Marchetti P, Marini L, (1994) Combined effects of estradiol, leuprorelin, tamoxifen and medroxyprogesterone acetate on cell growth and steroid hormone receptors in breast cancer cells. J Cancer Res Clin Oncol 120: 605-609.
18. Sica G, Iacopino F, Settesoldi D, Zelano G, (1999) Effect of leuprorelin acetate on cell growth and prostate-specific antigen gene expression in human prostatic cancer cells. Eur Urol 35: 2-8.
19. Sica G, Schinzari G, Angelucci C, Lama G, Iacopino F, (2001) Direct effects of GnRH agonists in human hormone-sensitive endometrial cells. Mol Cell Endocrinol 176: 121-128.
20. Sica G, Zelano G, Settesoldi D, Iacopino F, (2003) Regulation of prostate-specific antigen gene expression by an LH-RH analogue in human prostatic cells. Anticancer Res 23: 1283-1287.
21. Angelucci C, Iacopino F, Lama G, Capucci S, Zelano G, et al. (2004) Apoptosis-related gene expression affected by a GnRH analogue without induction of programmed cell death in LNCaP cells. Anticancer Res 24: 2729-2738.
22. Iacopino F, Lama G, Angelucci C, Sica G, (2006) Leuprorelin acetate affects ERK1/2 activity in prostate cancer cells. Int J Oncol 29: 237-247.
23. Angelucci C, Lama G, Iacopino F, Sica G, (2011) Leuprorelin acetate affects adhesion molecule expression in human prostate cancer cells. Int J Oncol 38: 1501-1509.
24. Angelucci C, Lama G, Iacopino F, Ferracuti S, Bono AV, et al. (2009) GnRH receptor expression in human prostate cancer cells is affected by hormones and growth factors. Endocrine 36: 87-97.
25. Morgan K, Stewart AJ, Miller N, Mullen P, Muir M, et al. (2008) Gonadotropin-releasing hormone receptor levels and cell context affect tumor cell responses to agonist in vitro and in vivo. Cancer Res 68: 6331-6340.
26. De Spirito M, Missori M, Papi M, Maulucci G, Teiera J, et al. (2008) Modifications in solvent clusters embedded along the fibers of a cellulose polymer network cause paper degradation. Phys Rev E: Stat Phys, Plasmas, Fluids 77: 41801.
27. Brunelli R, Papi M, Arcovito G, Bompiani A, Castagnola, et al. (2007) Globular structure of human ovulatory cervical mucus. FASEB J 21: 3872-3876.
28. Papi M, Arcovito G, De Spirito M, Vassalli M, Tiribilli B, (2006) Fluids viscosity determination by using uncalibrated atomic force microscopy cantilevers. Appl Phys Lett 88: 194102, 1 3.
29. Papi M, Maulucci G, Arcovito G, Paoletti P, Vassalli M, et al. (2008) Detection of microviscosity using uncalibrated atomic force microscopy cantilevers. Appl Phys Lett 93: 124102, 1-3.
30. De Spirito M, Brunelli R, Mei G, Bertani FR, Ciasca G, et al. (2006) Low density lipoprotein aged in plasma forms clusters resembling subendothelial droplets: aggregation via surface sites. Biophys J 90: 4239-4247.
31. Parasassi T, De Spirito M, Mei G, Brunelli R, Greco G, et al. (2008) Low density lipoprotein misfolding and amyloidogenesis. FASEB J 22(7): 2350-2356.
32. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW, (1979) Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17: 16-23.
33. Anderson L, Mc Gregor A, Cook JV, Chilvers E, Eidne KA, (1995) Rapid desensitization of GnRH-stimulated intracellular signalling events in alpha T3-1 and HEK-293 cells expressing the GnRH receptor. Endocrinology 136 (11) (): 5228-31.
34. Papi M, Sylla L, Parasassi T, Brunelli R, Monaci M, et al. (2009) Evidence of elastic to plastic transition in the zona pellucida of oocytes using atomic force spectroscopy. App Phys Lett 94: 153902.
35. Soumetz FC, Saenz JF, Pastorino L, Ruggiero C, Nosi D, et al. (2010) Investigation of integrin expression on the surface of osteoblast-like cells by atomic force microscopy. Ultramicroscopy 110: 330-338.
36. Papi M, Brunelli R, Sylla L, Parasassi T, Monaci M, et al. (2010) Mechanical properties of zona pellucida hardening. Eur Biophy J 39: 987-992.
37. Limonta P, Moretti RM, Montagnani Marelli M, Dondi D, Parenti M, et al. (1999) The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway. Endocrinology 140: 5250-5256.
38. D'Onofrio A, (2005) A general framework for modeling tumor-immune system competition and immunotherapy: Mathematical analysis and biomedical inferences. Physica D 208: 220-235.
39. Wormald PJ, Eidne KA, Millar RP, (1985) Gonadotropin-releasing hormone receptors in human pituitary: ligand structural requirements, molecular size, and cationic effects. J Clin Endocrinol Metab 61: 1190-1194.
40. Dobkin-Bekman M, Naidich M, Pawson AJ, Millar RP, Seger R, et al. (2006) Activation of mitogen-activated protein kinase (MAPK) by GnRH is cell-context dependent. Mol Cell Endocrinol 252: 184-190.
41. Kaiser UB, Jakubowiak A, Steinberger A, Chin WW, (1993) Regulation of rat pituitary gonadotropin-releasing hormone receptor mRNA levels in vivo and in vitro. Endocrinology 133: 931-934.
42. Yasin M, Dalkin AC, Haisenleder DJ, Kerrigan JR, Marshall JC, (1995) Gonadotropin-releasing hormone (GnRH) pulse pattern regulates GnRH receptor gene expression: augmentation by estradiol. Endocrinology 136: 1559-1564.
43. Tieva A, Bergh A, Damber JE, (2003) The clinical implications of the difference between castration, gonadotrophin releasing-hormone (GnRH) antagonists and agonist treatment on the morphology and expression of GnRH receptors in the rat ventral prostate. BJU Int 91: 227-233.
44. Bono AV, Salvadore M, Celato N, (2002) Gonadotropin-releasing hormone receptors in prostate tissue. Anal Quant Cytol Histol 24: 221-227.
45. Lamharzi N, Halmos G, Jungwirth A, Schally AV, (1998) Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice. Int J Oncol 13: 429-435.
46. Castellón E, Clementi M, Hitschfeld C, Sánchez C, Benítez D, et al. (2006) Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma. Cancer Invest 24: 261-268.
47. Zhang X, Bao L, Guan JS, (2006) Role of delivery and trafficking of delta-opioid peptide receptors in opioid analgesia and tolerance. Trends Pharmacol Sci 27: 324-329.
48. McArdle CA, Franklin J, Green L, Hislop JN, (2002) Signalling, cycling and desensitisation of gonadotrophin-releasing hormone receptors. J Endocrinol 173: 1-11.
49. White CD, Stewart AJ, Lu ZL, Millar RP, Morgan K, (2008) Antiproliferative effects of GnRH agonists: prospects and problems for cancer therapy. Neuroendocrinology 88: 7-79.
50. Plosker GL, Brogden RN, (1994) Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders. Drugs 48: 930-967.
51. Ravenna L, Salvatori L, Morrone S, Lubrano C, Cardillo MR, et al. (2000) Effects of triptorelin, a gonadotropin-releasing hormone agonist, on the human prostatic cell lines PC3 and LNCaP. J Androl 21: 549-557.
52. Lin X, Cornea A, Janovick JA, Conn PM, (1998) Visualization of unoccupied and occupied gonadotropin-releasing hormone receptors in living cells. Mol Cell Endocrinol 146: 27-37.